Last reviewed · How we verify
BPO
BPO (benzoyl peroxide) kills acne-causing bacteria and reduces sebum production while promoting skin cell turnover.
BPO (benzoyl peroxide) kills acne-causing bacteria and reduces sebum production while promoting skin cell turnover. Used for Acne vulgaris (mild to moderate), Acne rosacea (adjunctive).
At a glance
| Generic name | BPO |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | Topical antimicrobial and keratolytic agent |
| Target | Cutibacterium acnes (bacterial target); non-specific oxidative mechanism |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Benzoyl peroxide is an antimicrobial and keratolytic agent that generates reactive oxygen species to eliminate Cutibacterium acnes (formerly Propionibacterium acnes). It also has mild comedolytic properties that help unclog pores and reduce inflammatory lesions. The drug does not induce bacterial resistance, making it a durable first-line treatment for acne.
Approved indications
- Acne vulgaris (mild to moderate)
- Acne rosacea (adjunctive)
Common side effects
- Skin irritation, erythema, and dryness
- Peeling and desquamation
- Contact dermatitis or allergic reaction
- Bleaching of hair or fabrics
Key clinical trials
- The Effects of Holmium Laser Enucleation and Thulium Laser Enucleation on Continence, Urethral Stricture, and Sexual Function in Benign Prostatic Hyperplasia
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Early Versus Delayed Trial Without Catheter in Men With Acute Urinary Retention. (NA)
- SteamOne - Prospective Database for Rezum Water Vapor Therapy of the Prostate
- Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel (PHASE2)
- Registry of MIUS for Benign Prostatic Obstruction
- Uroflowmetry and IPSS Factors Influencing Surgical Decision
- Association Between Qmax/eGFR Ratio and LUTS Severity in Men Over 40
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPO CI brief — competitive landscape report
- BPO updates RSS · CI watch RSS
- Galderma R&D portfolio CI